MEDP Q2 FY2026 earnings call — BigGo Finance
Medpace (MEDP) reported Q2 FY2026 revenue of $707.3M, up 17.2% YoY, with net book-to-bill of 1.13. Net income rose 34.5% to $121.4M, EPS was $4.25, and operating cash flow was $162M. Backlog ended at $3.0B. FY2026 guidance raised to revenue $2.805–2.885B and EPS $17.25–$17.95.
How this was made
The 30-second read
Why it matters
The call provides a fresh guidance raise and operational updates that directly affect forward revenue, margin, and EPS expectations, with the main risk being elevated backlog burn rate and potential cancellation volatility.
Market read
Traders can update models immediately using the raised FY2026 revenue, EBITDA, and EPS ranges plus the operational drivers (net awards, cancellations, backlog conversion expectations).
What to watch
Pre-backlog is larger than backlog and growing faster, but the article notes cancellations remain unpredictable; traders should monitor whether oncology mix strength persists into subsequent quarters.
Background
Medpace is a clinical research organization; its earnings focus on bookings (net new business awards), book-to-bill, cancellations, backlog, and backlog conversion (burn rate).
Ticker impact
Medpace raised FY2026 guidance to $2.805B-$2.885B revenue and $17.25-$17.95 EPS after Q2 results beat consensus, with net book-to-bill 1.13.
Likely positive bias for the stock into the next earnings cycle, with volatility risk if cancellations or backlog conversion underperform the raised outlook.
The article discloses a full set of primary earnings datapoints and explicit FY2026 guidance ranges, including the main operational drivers (net awards, cancellations, backlog conversion expectations).
Market effects
A strong CRO bookings and guidance raise can reinforce read-across optimism for clinical trial services demand, especially oncology-heavy programs.
No direct regional shock; headcount growth expectations emphasize U.S. and India scaling.
Limited global spillover beyond CRO demand signals and oncology trial mix trends.
Counterpoint
The backlog burn rate is elevated at 24.1% versus historical ~18%, so the raised outlook could be sensitive to conversion timing if gating conservatism reverses.
Key entities
- companyMedpace Holdings, Inc.
Subject of the earnings call, reporting Q2 FY2026 results and raising FY2026 guidance.
- executiveAugust Troendle
Management speaker providing commentary on bookings, cancellations, backlog burn rate drivers, and guidance assumptions.
